

## Obrindatamab

Cat. No.:	HY-P99762
CAS No.:	2069959-72-2
Target:	CD3
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer <sup>[1]</sup> .									
In Vitro	<p>MGD009 (MGD009) binds human and cynomolgus monkey CD3 and B7-H3 with K<sub>D</sub> values of 13.9, 14.7, 24.6, and 30.2 nM for human CD3ε/δ, cynomolgus CD3ε/δ, human B7-H3-His, and cynomolgus B7-H3-His, respectively<sup>[1]</sup>.</p> <p>Obrindatamab (0.01-1000 ng/mL; A498, U87, 22Rv1, and Detroit562 cells) mediates redirected killing of multiple B7-H3-expressing tumor lines<sup>[1]</sup>.</p> <p>Obrindatamab (0.01-1000 ng/mL; PBMCs and A498 cells) mediated T-cell activation and proliferation is target antigen dependent<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Obrindatamab (MGD009; 0.004-1 mg/kg; i.v.) inhibits growth and tumor regression of B7-H3-expressing tumor xenografts in human T cell or PBMC-reconstituted mice<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cellreconstituted NSG b2m<sup>-/-</sup> mice, Established tumor model in human T-cell reconstituted MHC1<sup>-/-</sup> mice<sup>[1]</sup></td></tr><tr><td>Dosage:</td><td>0.004-1 mg/kg</td></tr><tr><td>Administration:</td><td>intravenous injection</td></tr><tr><td>Result:</td><td>Had antitumor activity in multiple in vivo models.</td></tr></table>		Animal Model:	NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cellreconstituted NSG b2m <sup>-/-</sup> mice, Established tumor model in human T-cell reconstituted MHC1 <sup>-/-</sup> mice <sup>[1]</sup>	Dosage:	0.004-1 mg/kg	Administration:	intravenous injection	Result:	Had antitumor activity in multiple in vivo models.
Animal Model:	NOD/SCID mice with Co-mix mouse xenograft model, Established tumor model in human T-cellreconstituted NSG b2m <sup>-/-</sup> mice, Established tumor model in human T-cell reconstituted MHC1 <sup>-/-</sup> mice <sup>[1]</sup>									
Dosage:	0.004-1 mg/kg									
Administration:	intravenous injection									
Result:	Had antitumor activity in multiple in vivo models.									

### REFERENCES

[1]. Paul M, et, al. MGD009, a B7-H3 x CD3 Bispecific Dual-Affinity Re-Targeting (DART®) Molecule Directing T Cells to Solid Tumors.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA